Search Results
Update on selinexor for myeloma and large cell lymphomas
Myeloma & selinexor in 2020
Key novel agents for relapsed diffuse large B-cell lymphoma
Selinexor, selective inhibitor of nuclear export, for non-Hodgkin lymphoma
Phase 2 Trial of Selinexor Shows Durable Responses in DLBCL
Dr. Hill on the FDA Approval of Selinexor in DLBCL
Selinexor in myelofibrosis treatment
Dr. Hill on the Safety Profile of Selinexor in Relapsed/Refractory DLBCL
All About Xpovio (Selinexor)
All About XPOVIO (selinexor) #myeloma
Dr. Hill on the SADAL Trial With Selinexor in DLBCL
Selinexor combination regimens reduce toxicity
